Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betaferon single-dose versus double-dose in early secondary progressive multiple sclerosis
2005-001540-23Phase 3Terminated
- Sponsor
- Schering Nordiska
- Start
- Sep 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of interferon beta-1a in secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by Schering Nordiska. Primary endpoint: Cumulative number of new or enlarging T2 lesions. Started Sep 2005; status: terminated.
02
Drugs
interferon beta-1a
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2005-001540-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001540-23.